Tyck till om SwePub Sök
här!
Sökning: WFRF:(Poikonen Saksela Paula)
> Lahdenperä Outi >
Adjuvant Capecitabi...
-
Joensuu, HeikkiHelsinki Univ Hosp, Dept Oncol, Helsinki, Finland.;Univ Helsinki, Helsinki, Finland.
(författare)
Adjuvant Capecitabine for Early Breast Cancer : 15-Year Overall Survival Results From a Randomized Trial
- Artikel/kapitelEngelska2022
Förlag, utgivningsår, omfång ...
-
American Society of Clinical Oncology (ASCO),2022
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-476622
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-476622URI
-
https://doi.org/10.1200/JCO.21.02054DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
PURPOSE: Few data are available regarding the influence of adjuvant capecitabine on long-term survival of patients with early breast cancer.METHODS: The Finland Capecitabine Trial (FinXX) is a randomized, open-label, multicenter trial that evaluates integration of capecitabine to an adjuvant chemotherapy regimen containing a taxane and an anthracycline for the treatment of early breast cancer. Between January 27, 2004, and May 29, 2007, 1,500 patients with axillary node-positive or high-risk node-negative early breast cancer were accrued. The patients were randomly allocated to either TX-CEX, consisting of three cycles of docetaxel (T) plus capecitabine (X) followed by three cycles of cyclophosphamide, epirubicin, and capecitabine (CEX, 753 patients), or to T-CEF, consisting of three cycles of docetaxel followed by three cycles of cyclophosphamide, epirubicin, and fluorouracil (CEF, 747 patients). We performed a protocol-scheduled analysis of overall survival on the basis of approximately 15-year follow-up of the patients.RESULTS: The data collection was locked on December 31, 2020. By this date, the median follow-up time of the patients alive was 15.3 years (interquartile range, 14.5-16.1 years) in the TX-CEX group and 15.4 years (interquartile range, 14.8-16.0 years) in the T-CEF group. Patients assigned to TX-CEX survived longer than those assigned to T-CEF (hazard ratio 0.81; 95% CI, 0.66 to 0.99; P = .037). The 15-year survival rate was 77.6% in the TX-CEX group and 73.3% in the T-CEF group. In exploratory subgroup analyses, patients with estrogen receptor-negative cancer and those with triple-negative cancer treated with TX-CEX tended to live longer than those treated with T-CEF.CONCLUSION: Addition of capecitabine to a chemotherapy regimen that contained docetaxel, epirubicin, and cyclophosphamide prolonged the survival of patients with early breast cancer.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Kellokumpu-Lehtinen, Pirkko-LiisaTampere Univ Hosp, Dept Oncol, Tampere, Finland.;Tampere Univ, Tampere, Finland.
(författare)
-
Huovinen, RiikkaTurku Univ Hosp, Dept Oncol, Turku, Finland.
(författare)
-
Jukkola, ArjaTampere Univ Hosp, Dept Oncol, Tampere, Finland.;Tampere Univ, Tampere, Finland.;Oulu Univ Hosp, Dept Radiotherapy & Oncol, Oulu, Finland.
(författare)
-
Tanner, MinnaTampere Univ Hosp, Dept Oncol, Tampere, Finland.;Tampere Univ, Tampere, Finland.
(författare)
-
Ahlgren, JohanGävle Cent Hosp, Gävle, Sweden.;Acad Hosp, Reg Canc Ctr Mid Sweden, Uppsala, Sweden.
(författare)
-
Auvinen, PäiviKuopio Univ Hosp, Ctr Canc, Kuopio, Finland.
(författare)
-
Lahdenperä, OutiTurku Univ Hosp, Dept Oncol, Turku, Finland.
(författare)
-
Villman, KennethÖrebro Univ Hosp, Örebro, Sweden.
(författare)
-
Nyandoto, PaulPaijat Hame Cent Hosp, Lahti, Finland.
(författare)
-
Nilsson, GregerUppsala universitet,Experimentell och klinisk onkologi,Gävle Cent Hosp, Dept Oncol, Sweden.;Visby Hosp, Sweden.(Swepub:uu)grnil933
(författare)
-
Poikonen-Saksela, PaulaHelsinki Univ Hosp, Dept Oncol, Helsinki, Finland.;Univ Helsinki, Helsinki, Finland.
(författare)
-
Kataja, VesaCent Finland Cent Hosp, Jyvaskyla, Finland.
(författare)
-
Bono, PetriHelsinki Univ Hosp, Dept Oncol, Helsinki, Finland.;Univ Helsinki, Helsinki, Finland.
(författare)
-
Junnila, JouniEstiMates, Turku, Finland.
(författare)
-
Lindman, HenrikUppsala universitet,Experimentell och klinisk onkologi(Swepub:uu)henrlind
(författare)
-
Helsinki Univ Hosp, Dept Oncol, Helsinki, Finland.;Univ Helsinki, Helsinki, Finland.Tampere Univ Hosp, Dept Oncol, Tampere, Finland.;Tampere Univ, Tampere, Finland.
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Journal of Clinical Oncology: American Society of Clinical Oncology (ASCO)40:10, s. 1051-10580732-183X1527-7755
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Joensuu, Heikki
-
Kellokumpu-Lehti ...
-
Huovinen, Riikka
-
Jukkola, Arja
-
Tanner, Minna
-
Ahlgren, Johan
-
visa fler...
-
Auvinen, Päivi
-
Lahdenperä, Outi
-
Villman, Kenneth
-
Nyandoto, Paul
-
Nilsson, Greger
-
Poikonen-Saksela ...
-
Kataja, Vesa
-
Bono, Petri
-
Junnila, Jouni
-
Lindman, Henrik
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Journal of Clini ...
- Av lärosätet
-
Uppsala universitet